Long-acting formulations of somatostatin analogues

Italian Journal of Gastroenterology and Hepatology

Volumn 31, Issue 7 SUPPL. 2, 1999, Pages

  Anthony, L B ^a,b  

^a Lousiana State University School of Medicine   (United States)

^b TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Endocrine tumours; Lanreotide; Octreotide; Somatostatin analogue

Indexed keywords

ANGIOPEPTIN; OCTREOTIDE; SOMATOSTATIN DERIVATIVE;

CARCINOID SYNDROME; CHOLELITHIASIS; CLINICAL TRIAL; CONFERENCE PAPER; DIARRHEA; FEVER; HOT FLUSH; HUMAN; HYPOTHYROIDISM; INTRAMUSCULAR DRUG ADMINISTRATION; MULTICENTER STUDY; MUSCLE WEAKNESS; NEPHROLITHIASIS; RASH; SLOW RELEASE FORMULATION;

EID: 0032730198     PISSN: 11258055     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (9)

1. Lancranjan I, Bruns C, Grass P, Jaquet P, Jervell J, Kendall-Taylor P, et al. Sandostatin LAR®: pharmacokinetics, pharmakodynamics, efficacy, and tolerability in acromegalic patients. Metabolism 1995;44(Suppl l):18-26.
2. Khun JM, Legrand A, Ruiz JM, Obach R, De Ronzan J, Thomas F. Pharmacokinetic and pharmacodynamic properties of a long-acting formulation of the new somatostatin analogue, lanreotide in normal healthy volunteers. Br J Clin Pharmac 1994;38:213-9.
3. Heron I, Thomas F, Dero M, Cancel A, Ruiz JM, Schatz B, et al. Pharmacokinetics and efficacy of a long-acting formulation of the new somatostatin analog BIM 32014 in patients with acromegaly. J Clin Endocrinol Metab 1993;76:721-7.
4. Giusti M, Ciccarelli E, Dallabonzana D, Delitala G, Faglia G, Liuzzi A, et al. Clinical results of long-term slow-release lanreotide treatment of acromegaly. Eur J Clin Invest. 1997;27:277-84.
5. Caron P, Morange-Ramos I, Cogne M, Jaquet P. Three year follow-up of acromegalic patients treated with intramuscular slow-release lanreotide. J Clin Endocrinol Metab 1997;82:18-22.
6. Ruszniewski P, Decreux M, Chayvialle JA, Blumberg J, Cloarec D, Michel H, et al. Treatment of the carcinoid syndrome with the long-acting somatostatin analogue lanreotide: A prospective study in 39 patients. Gut 1996;39:279-83.
7. Caron P, Cogne M, Gusthiot-Joudet B, Wakim S, Catus F, Bayard F. Intramuscular injections of slow-release lanreotide (BIM 23014) in acromegalic patients previously treated with continuous subcutaneous infusion of octreotide (SMS 201-995). Eur J Endocrinol 1995;132:320-5.
8. McCarthy KE, Weltering EA, Espenan GD, Cronin M, Maloney TJ, Anthony LB. In situ radiotherapy with 111-In-pentatreotide: initial observations and future directions. Cancer J Sci Am 1998;4:94-10.
9. deJong M, Breeman WA, Bakker WH, Kooij PP. Bernard BF, Hofland LJ, et al. Comparison of 111-In-labeled somatostatin analogs for tumor scintigraphy and radionuclide therapy. Cancer Res 1998;58:437-41.